» Articles » PMID: 27896684

Use of Spray-Dried Dispersions in Early Pharmaceutical Development: Theoretical and Practical Challenges

Overview
Journal AAPS J
Specialty Pharmacology
Date 2016 Nov 30
PMID 27896684
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Spray-dried dispersions (SDDs) have become an important formulation technology for the pharmaceutical product development of poorly water-soluble (PWS) compounds. Although this technology is now widely used in the industry, especially in the early-phase development, the lack of mechanistic understanding still causes difficulty in selecting excipients and predicting stability of SDD-based drug products. In this review, the authors aim to discuss several principles of polymer science pertaining to the development of SDDs, in terms of selecting polymers and solvents, optimizing drug loading, as well as assessing physical stability on storage and supersaturation maintenance after dissolution, from both thermodynamic and kinetic considerations. In order to choose compatible solvents with both polymers and active pharmaceutical ingredients (APIs), a symmetric Flory-Huggins interaction (Δχ ∼0) approach was introduced. Regarding spray drying of polymer-API solutions, low critical solution temperature (LCST) was discussed for setting the inlet temperature for drying. In addition, after being exposed to moisture, SDDs are practically converted to ternary systems with asymmetric Flory-Huggins interactions, which are thermodynamically not favored. In this case, the kinetics of phase separation plays a significant role during the storage and dissolution of SDD-based drug products. The impact of polymers on the supersaturation maintenance of APIs in dissolution media was also discussed. Moreover, the nature of SDDs, with reference to solid solution and the notion of solid solubility, was examined in the context of pharmaceutical application. Finally, the importance of robust analytical techniques to characterize the SDD-based drug products was emphasized, considering their complexity.

Citing Articles

Mechanochemically Induced Solid-State Transformations of Levofloxacin.

Kadri L, Carta M, Lampronti G, Delogu F, Tajber L Mol Pharm. 2024; 21(6):2838-2853.

PMID: 38662637 PMC: 11151213. DOI: 10.1021/acs.molpharmaceut.4c00008.


Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.

Barrs V, Hobi S, Wong A, Sandy J, Shubitz L, Beczkowski P J Feline Med Surg. 2024; 26(1):1098612X231220047.

PMID: 38189264 PMC: 10949877. DOI: 10.1177/1098612X231220047.


HPMCAS-Based Amorphous Solid Dispersions in Clinic: A Review on Manufacturing Techniques (Hot Melt Extrusion and Spray Drying), Marketed Products and Patents.

Corrie L, Ajjarapu S, Banda S, Parvathaneni M, Bolla P, Kommineni N Materials (Basel). 2023; 16(20).

PMID: 37895598 PMC: 10608006. DOI: 10.3390/ma16206616.


Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics.

Bhalani D, Nutan B, Kumar A, Chandel A Biomedicines. 2022; 10(9).

PMID: 36140156 PMC: 9495787. DOI: 10.3390/biomedicines10092055.


Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability.

Yang L, Wu P, Xu J, Xie D, Wang Z, Wang Q AAPS PharmSciTech. 2021; 22(4):142.

PMID: 33893566 DOI: 10.1208/s12249-021-02005-x.


References
1.
Chauhan H, Hui-Gu C, Atef E . Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013; 102(6):1924-1935. DOI: 10.1002/jps.23539. View

2.
Yu L . Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1):27-42. DOI: 10.1016/s0169-409x(01)00098-9. View

3.
Mohammad M, Alhalaweh A, Velaga S . Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm. 2011; 407(1-2):63-71. DOI: 10.1016/j.ijpharm.2011.01.030. View

4.
Brouwers J, Brewster M, Augustijns P . Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J Pharm Sci. 2009; 98(8):2549-72. DOI: 10.1002/jps.21650. View

5.
Ilevbare G, Liu H, Pereira J, Edgar K, Taylor L . Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir. Mol Pharm. 2013; 10(9):3392-403. DOI: 10.1021/mp400228x. View